Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)
Clinical trial NCT03099161 · TERMINATED
Trial details
- NCT number
- NCT03099161
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-27
- Primary completion
- 2017-11-24
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.